TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs

Journal name:
Nature
Volume:
467,
Pages:
986–990
Date published:
DOI:
doi:10.1038/nature09459
Received
Accepted
Published online

Aberrant expression of microRNAs (miRNAs) and the enzymes that control their processing have been reported in multiple biological processes including primary and metastatic tumours1, 2, 3, 4, 5, 6, but the mechanisms governing this are not clearly understood. Here we show that TAp63, a p53 family member, suppresses tumorigenesis and metastasis, and coordinately regulates Dicer and miR-130b to suppress metastasis. Metastatic mouse and human tumours deficient in TAp63 express Dicer at very low levels, and we found that modulation of expression of Dicer and miR-130b markedly affected the metastatic potential of cells lacking TAp63. TAp63 binds to and transactivates the Dicer promoter, demonstrating direct transcriptional regulation of Dicer by TAp63. These data provide a novel understanding of the roles of TAp63 in tumour and metastasis suppression through the coordinate transcriptional regulation of Dicer and miR-130b and may have implications for the many processes regulated by miRNAs.

At a glance

Figures

  1. TAp63-/- mice develop metastatic tumours.
    Figure 1: TAp63−/− mice develop metastatic tumours.

    a, b, Metastatic mammary adenocarcinoma in lung (LU; a) and brain (BR; b). c, Tumour-free survival curves; n = 30 and P0.05. WT, wild type. d, Tumour spectra of the indicated mice genotypes; n = 30. e, LOH analysis of TAp63 in sarcomas (S) and carcinomas (C) from the indicated genotypes. f, g, Percentage of metastatic sarcomas and carcinomas (f) and multiple malignancies (g); n = 30. h, i, Metastatic squamous cell carcinoma (SCC) on skin (h) and in lung (LU; i). j, k, Tumour spectrum (j) and metastases (k) of the indicated mice genotypes; n = 30. Asterisk, statistical difference between TAp63/p53 mutant and p53+/− or p53−/− mice; two asterisks, statistical difference between two double-mutant genotypes; P0.05. l, m, PCR analysis for LOH of TAp63 (l) or p53 (m) in carcinomas (C) and sarcomas (S) of the indicated genotypes.

  2. TAp63-deficient tumours show high levels of senescence and genomic instability.
    Figure 2: TAp63-deficient tumours show high levels of senescence and genomic instability.

    a, b, Non-metastatic osteosarcoma (a) and metastatic lung adenocarcinoma (LA) in kidney (KI) (b) from TAp63−/−;p53+/− mouse. c, Percentage of SA-β-gal-positive sarcomas; n = 6 of each genotype. d, Quantitative real-time polymerase chain reaction (qRT-PCR) for markers of senescence (PML, p16Ink4a and p19Arf) in the indicated tumours; n = 6 of each genotype. e, Percentage of TAp63−/− and TAp63+/− tumours with chromosomal aberrations determined by metaphase spreads; n = 6 of each genotype. Frag/DM, fragmented, double-minute chromosome. f, Representative metaphase spread from a TAp63−/− tumour. Coloured arrows indicate aberrations: rings (red arrows) and double minutes (blue arrow). g, Invasion assays in wild-type MEFs (n = 3) and TAp63−/− MEFs (n = 3). h, qRT-PCR for TAp63 in the indicated human squamous cell carcinoma (HNSCC) cell lines; n = 5. i, Invasion assays in HNSCC cell lines; n = 5. Error bars indicate s.e.m. Asterisk, P0.05.

  3. TAp63 regulates metastasis by transcriptional activation of Dicer.
    Figure 3: TAp63 regulates metastasis by transcriptional activation of Dicer.

    ac, qRT-PCR of Dicer mRNA in murine tumours (a), MEFs (b) and HNSCC cell lines (c); n = 5. d, qRT-PCR of ChIP assay using keratinocytes and indicating p63-binding site (p63BS) and nonspecific binding site (NSBS) on Dicer promoter; n = 3. e, Luciferase assay for Dicer; n = 5. V, pcDNA3 vector. f, Western blot analysis for Dicer expression in MEFs infected with the indicated vectors. g, h, Invasion assays of MEFs expressing Dicer (g) and MEFs expressing shRNA-Dicer (h); n = 3. i, qRT-PCR for Dicer in MEFs expressing TAp63γ; n = 3. j, Invasion assays of MEFs expressing TAp63γ; n = 3. k, qRT-PCR for Dicer in wild-type (TAp63fl/fl) and TAp63-ablated (TAp63Δ/Δ) MEFs; n = 3. l, Invasion assays of TAp63Δ/Δ MEFs; n = 3. m, Northern blot analysis for the indicated mature miRNAs in wild-type and TAp63−/− MEFs. n, o, Northern blot analysis for miR-10b (n) or miR-130b (o) using MEFs of the indicated genotypes expressing vector (V) or TAp63γ. Error bars indicate s.e.m. Asterisk, P0.05.

  4. TAp63 regulates miR-130b in metastasis.
    Figure 4: TAp63 regulates miR-130b in metastasis.

    ac, TaqMan reverse-transcriptase-mediated PCR (RT–PCR) for miR-130b and miR-34a in MEFs (a), murine tumours (b) and HNSCCs (c); n = 5. d, qRT-PCR of ChIP assay for miR-130b indicating p63-binding site (p63BS) and non-specific binding site (NSBS); n = 3. e, Luciferase assay for miR-130b; n = 3. f, g, TaqMan RT–PCR for miR-130b in wild-type and TAp63−/− MEFs expressing the indicated vectors (f) and wild-type (TAp63fl/fl) and TAp63-ablated (TAp63Δ/Δ) MEFs (g); n = 3. h, i, Invasion assays of MEFs infected with shRNA-miR-130b (sh-130b) (h) and wild-type and TAp63−/− MEFs expressing the indicated vectors (i); n = 3. Scrambled sequence (sc) shRNA was used as a negative control. Error bars indicate s.e.m. Asterisk, P0.05.

References

  1. Baffa, R. et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J. Pathol. 219, 214221 (2009)
  2. Gibbons, D. L. et al. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 23, 21402151 (2009)
  3. Ma, L., Teruya-Feldstein, J. & Weinberg, R. A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449, 682628 (2007)
  4. Kumar, M. S. et al. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 23, 27002704 (2009)
  5. Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 8348 (2005)
  6. Merritt, W. M. et al. Dicer, Drosha, and outcomes in patients with ovarian cancer. N. Engl. J. Med. 359, 26412650 (2008)
  7. Flores, E. R. The roles of p63 in cancer. Cell Cycle 6, 300304 (2007)
  8. Flores, E. R. et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7, 363373 (2005)
  9. Keyes, W. M. et al. p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors. Proc. Natl Acad. Sci. USA 103, 84358440 (2006)
  10. Yang, A., Kaghad, M., Caput, D. & McKeon, F. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet. 18, 9095 (2002)
  11. Hibi, K. et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc. Natl Acad. Sci. USA 97, 54625467 (2000)
  12. Park, B. J. et al. Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res. 60, 33703374 (2000)
  13. Urist, M. J. et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am. J. Pathol. 161, 11991206 (2002)
  14. Park, H. R. et al. Low expression of p63 and p73 in osteosarcoma. Tumori 90, 239243 (2004)
  15. Yang, A. et al. p63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2, 305316 (1998)
  16. Jacks, T. et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 17 (1994)
  17. Lang, G. A. et al. Gain of function of a p53 hot spot mutation in a mouse model of Li–Fraumeni syndrome. Cell 119, 861872 (2004)
  18. Olive, K. P. et al. Mutant p53 gain of function in two mouse models of Li–Fraumeni syndrome. Cell 119, 847860 (2004)
  19. Su, X. et al. TAp63 prevents premature aging by promoting adult stem cell maintenance. Cell Stem Cell 5, 6475 (2009)
  20. Maruya, S. et al. Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin. Cancer Res. 10, 38253830 (2004)
  21. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 32433248 (2001)
  22. Kumar, M. S. et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nature Genet. 39, 673677 (2007)
  23. He, L. et al. A microRNA component of the p53 tumour suppressor network. Nature 447, 11301134 (2007)
  24. Flores, E. R. et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416, 560564 (2002)
  25. Pruneri, G. et al. The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification. J. Pathol. 206, 337345 (2005)
  26. Mudhasani, R. et al. Loss of miRNA biogenesis induces p19Arf-p53 signaling and senescence in primary cells. J. Cell Biol. 181, 10551063 (2008)
  27. Su, X. et al. Rescue of key features of the p63-null epithelial phenotype by inactivation of Ink4a and Arf . EMBO J. 28, 19041915 (2009)
  28. Landthaler, M. et al. Molecular characterization of human Argonaute-containing ribonucleoprotein complexes and their bound target mRNAs. RNA 14, 25802596 (2008)
  29. Lin, Y. L. et al. p63 and p73 transcriptionally regulate genes involved in DNA repair. PLoS Genet. 5, e1000680 (2009)

Download references

Author information

  1. These authors contributed equally to this work.

    • Xiaohua Su &
    • Deepavali Chakravarti

Affiliations

  1. Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA

    • Xiaohua Su,
    • Deepavali Chakravarti,
    • Min Soon Cho,
    • Lingzhi Liu,
    • Young Jin Gi,
    • Yu-Li Lin,
    • Marco L. Leung &
    • Elsa R. Flores
  2. Graduate School of Biomedical Sciences, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA

    • Deepavali Chakravarti,
    • Min Soon Cho &
    • Elsa R. Flores
  3. Department of Pathology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA

    • Adel El-Naggar,
    • Milind B. Suraokar &
    • Ignacio Wistuba
  4. Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA

    • Chad J. Creighton

Contributions

X.S., D.C. and E.R.F. designed the experiments and analysed the data. X.S., D.C., M.S.C., L.L., Y.J.G., Y.-L.L. and M.L.L. performed the experiments. A.E.-N. performed pathology analysis and provided human HNSCC samples. M.B.S. and I.W. provided human lung adenocarcinoma pathology information and RNA samples. C.J.C. performed statistical analysis on miRNA data. X.S., D.C. and E.R.F. wrote the manuscript. All authors discussed the results and commented on the manuscript.

Competing financial interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to:

Author details

Supplementary information

PDF files

  1. Supplementary Information (11.8M)

    This file contains Supplementary Figures 1-7 with legends and Supplementary Tables 1- 4.

Additional data